Status:

COMPLETED

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Lead Sponsor:

Celgene

Conditions:

Non-Small Cell Lung Cancer

Pancreatic Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This is a clinical trial examining the safety, pharmacokinetics, pharmacodynamics and efficacy of IV NPI-0052 (a proteasome inhibitor) in combination with oral vorinostat (Zolinza; a HDAC inhibitor) i...

Eligibility Criteria

Inclusion

  • Karnofsky Performance Status (KPS) at 70% or more.
  • Non-small cell lung cancer, pancreatic adenocarcinoma, melanoma or lymphoma for which a standard, approved therapy is not available. Patients must have lesions that are evaluable by RECIST criteria.
  • All Adverse Events of any prior chemotherapy, surgery, or radiotherapy, must have resolved to CTCAE (v. 3.0) Grade 1 or less(except for hemoglobin).
  • Adequate bone marrow, renal, liver function.
  • Signed informed consent.

Exclusion

  • Recent administration of chemotherapy, biological, immunotherapy or investigational agent, major surgery, or radiotherapy.
  • Intrathecal therapy.
  • Known brain metastases.
  • Significant cardiac disease.
  • Prior treatment with vorinostat or NPI-0052, or other HDACi (including valproic acid) or proteasome inhibitors.
  • Known allergy to any component of vorinostat. Prior hypersensitivity reaction of CTCAE Grade \> 3 to therapy containing propylene glycol or ethanol.
  • Pregnant or breast-feeding women.
  • Concurrent, active secondary malignancy for which the patient is receiving therapy.
  • Significant active infection.

Key Trial Info

Start Date :

March 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2010

Estimated Enrollment :

22 Patients enrolled

Trial Details

Trial ID

NCT00667082

Start Date

March 1 2008

End Date

January 1 2010

Last Update

November 22 2017

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Royal Adelaide Hospital

Adelaide, South Australia, Australia, 5000

2

The Queen Elizabeth Hospital

Woodville South, South Australia, Australia, 5011

3

Sir Charles Gairdner Hospital and University of Western Australia

Nedlands, Western Australia, Australia, 6009

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma | DecenTrialz